Amendment No. 5 to Schedule 13D by Novo Holdings A/S for Galecto, Inc.

This Amendment No. 5 to Schedule 13D, filed by Novo Holdings A/S, updates the ownership details of Galecto, Inc.'s Common Stock. Novo Holdings A/S, a Danish corporation wholly owned by the Novo Nordisk Foundation, reported that it ceased to be a beneficial owner of more than five percent of the Common Stock on October 7, 2025. The amendment details the sale of shares by Novo Holdings A/S in open market transactions on October 7, 2025, with prices ranging from $16.40 to $21.88 per share. Novo Holdings A/S now beneficially owns no securities of Galecto, Inc. The filing includes an updated Schedule I, incorporated by reference from a previous filing.